Markets
TER

Agilent's AATI Acquisition to Strengthen Portfolio, Footprint

Agilent Technologies, Inc.A entered into a definitive agreement to acquire privately held Advanced Analytical Technologies ("AATI") for $250 million.

Ankeny, IA-based, AATI is a developer of automated nucleic acid analysis systems using capillary electrophoresis methods. The company provides workflow solutions that include instruments, software and consumables. The solutions are extensively used for medical and molecular diagnostics for both commercial and research purposes.

The deal will strengthen Agilent's capillary electrophoresis solutions portfolio. It also expands the company's footprint in varied industries like pharmaceutical, life sciences, agriculture and biofuels.

Agilent shares closed at $69.70 on Mar 7, up 2.3%.

Acquisitions - Key Catalyst

Over the past few years, strategic acquisitions have played an important role in shaping Agilent's growth trajectory. The buyouts of Multiplicom NV (January 2017), Cobalt Light Systems (July 2017), Seahorse Bioscience and iLab Solutions (2016) has expanded its product portfolio.

Multiplicom deal expanded Agilent's genetic testing technology and product offerings. The Cobalt deal strengthened the company's presence in the high-growth Raman spectroscopy market. The iLab Solutions acquisition enabled the company to provide cloud-based laboratory management software.

Moreover, Seahorse Bioscience's technology was a strategic fit for Agilent's market-leading separations and mass spectrometry solutions, especially those that cater to metabolomics and disease research in pharma.

In the last quarter, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-readers based in-vitro cell assay kits. The technology targets important applications, namely cell metabolism, bioenergetics, drug toxicity, and hypoxia and oxidative stress. The acquisition expands Agilent's presence in the high-growth cell analysis market.

Agilent Technologies, Inc. Revenue (TTM)

Agilent Technologies, Inc. Revenue (TTM) | Agilent Technologies, Inc. Quote

Zacks Rank & Stocks to Consider

Currently, Agilent carries a Zacks Rank #3 (Hold).

Investors interested in the broader technology sector can consider Teradyne TER , AMETEK AME and Fortive Corporation FTV . While Teradyne sports a Zacks Rank #1 (Strong Buy), AMETEK and Fortive carry a Zacks Rank #2 (Buy), each. You can see the complete list of today's Zacks #1 Rank stocks here .

Long-term earnings growth rate for Teradyne, AMETEK and Fortive are currently pegged at 12%, 11.5% and 9.69%, respectively.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Agilent Technologies, Inc. (A): Free Stock Analysis Report

AMETEK, Inc. (AME): Free Stock Analysis Report

Teradyne, Inc. (TER): Free Stock Analysis Report

Fortive Corporation (FTV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TER AME FTV A

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More